All In MedTech

Device Trial Radar · NCT01628146

Prospective Investigation of SUPRACOR Visual Outcomes of Presbyopic Hyperopic Patients With and Without Astigmatism

PHASE IV STUDY # 1162. Prospective Investigation of SUPRACOR Visual Outcomes of Presbyopic Hyperopic Patients With and Without Astigmatism

Last checked: Nov 20, 2026Latest source record: May 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 2012

Primary completion

Jul 2015

Study completion Oct 2015

Sponsor

Lead sponsor
Technolas Perfect Vision GmbHNot on our public-company list
Sponsor type
Industry
First posted
Jun 26, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 45 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase IV study is an open, prospective, single-center, single-surgeon bilateral eye study to investigate the bilateral uncorrected intermediate visual acuity of presbyopic hyperopic patients, who have been treated with Presbyopia Algorithm SUPRACOR.

Conditions

  • Hyperopic Presbyopia

Interventions

  • SUPRACOR LASIK treatmentDevice

    The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. High contrast intermediate visual acuityTime frame: The study endpoints will be calculated for the 6-Month follow-up examination.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mater Private Hospital, Eye Laser Department

    Dublin, Ireland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.